AI in Research: How Smart Systems Are Changing the Way We Discover, Analyse, and Build
In October 2024, the Nobel Committee handed a Chemistry prize to a computer scientist. Demis Hassabis — the co-founder of DeepMind — shared the award with John Jumper and David Baker for work on protein structure prediction that fundamentally changed what biologists thought was possible. AlphaFold didn’t just solve a fifty-year-old scientific problem. It signalled, loudly, that AI had moved from a supporting role in research to something closer to the main event.
That’s the moment we keep coming back to when clients ask whether AI is really transforming research or whether it’s another wave of hype. The Nobel Committee tends not to give prizes for hype.
But here’s the complication that the headlines don’t usually get into: a 2025 analysis by MIT found that nearly 95% of enterprise AI pilots failed to deliver measurable business impact. Not because the models weren’t good enough. Because the systems weren’t integrated into real workflows, the data foundations were shaky, and nobody had figured out who owned the output. That tension — between the genuine transformative potential of AI in research and the high failure rate of generic implementations — is exactly what this piece is about.
We’ve built AI systems for clients across pharma, finance, and enterprise R&D. What we’ve learned is that the organisations getting real results aren’t the ones deploying the flashiest models. They’re the ones that built solutions around their specific pipelines, data, and workflows — and took the integration problem seriously from day one.
Reading the literature — a task that was quietly breaking research teams
Here’s a number that doesn’t get enough attention: scientific publications are growing at roughly 4% per year. There are now over 200 million research papers in circulation. A working researcher in most fields cannot possibly read even the fraction of literature that’s directly relevant to their work. The result is predictable — duplicate discoveries, missed connections between fields, and months spent on systematic reviews that should take weeks.
AI-powered literature tools change that picture substantially. A 2025 analysis of NLP-driven review tools found that a systematic review which traditionally takes 8–12 weeks could be completed in 3–4 weeks with AI assistance. The big time savings come from automated paper screening and multi-source synthesis — the grunt work that junior researchers used to spend weeks doing.
What’s actually happening under the hood is more interesting than the time-saving headline. Modern NLP models don’t just match keywords. They understand what a paper is actually claiming, extract methodology details, flag statistical significance, and surface relationships between studies that a keyword search would never find. A researcher looking for randomised controlled trials with specific outcome measures can query that in natural language and get ranked, relevant results rather than a list of 800 papers to screen manually.
The custom angle that matters here: off-the-shelf tools like Consensus or Elicit are genuinely useful for individual researchers. But for organisations — pharmaceutical companies, academic medical centres, enterprise R&D departments — the need is usually for something that integrates with existing databases, respects proprietary data, and outputs in formats that feed into internal workflows. That’s where custom machine learning development becomes necessary rather than optional.
Drug discovery: from years to months
Traditional drug discovery is brutally slow. Target identification, hit screening, lead optimisation, preclinical testing, then Phase I, II, and III trials — the average time from initial discovery to market approval stretches past 90 months. The cost runs into billions. And the failure rate at Phase III, after all of that investment, is still above 50%.
AI is compressing the early stages of that pipeline in ways that weren’t conceivable five years ago. The AI-native drug discovery market is projected to reach $7–8 billion by 2030, growing at over 32% annually — which reflects just how fast adoption is moving. More concretely: AI can reduce drug discovery costs by up to 40% and compress timelines from the traditional five-year window to 12–18 months for the early discovery phase.
AlphaFold is the headline story, but it’s not the only one. Generative AI models now design entirely novel molecular structures with specific properties built in — compounds that have never existed before, engineered for a target rather than discovered by screening. Researchers at MIT used generative AI in 2025 to design antibiotics effective against drug-resistant strains of gonorrhoea and Staphylococcus aureus — a class of problems where traditional approaches had essentially run out of ideas.
There’s an important caveat that doesn’t get discussed enough in the breathless coverage of these breakthroughs: AI accelerates the early phases, but clinical testing is still clinical testing. The biology doesn’t move faster because the molecule was designed by a model. What AI gives you is a dramatically better starting point and far fewer failed experiments before you get there.
Predictive analytics in clinical research
Clinical trials fail for a lot of reasons. Wrong patient population. Poorly designed endpoints. Protocol amendments mid-trial that delay everything. Recruitment that takes twice as long as planned — which is the case in about 80% of trials, according to a comprehensive 2025 review. These aren’t just delays. Each month of delay on a late-stage trial can cost north of a million dollars.
AI-powered predictive analytics addresses several of these failure modes. Machine learning models trained on historical trial data can predict patient dropout rates, flag protocol designs that have historically performed poorly for a given indication, and simulate trial outcomes before a single patient is enrolled. The evidence here is getting genuinely hard to dismiss: predictive analytics models achieve 85% accuracy in forecasting trial outcomes, and AI-assisted patient recruitment tools have improved enrollment rates by 65% in controlled studies.
On the patient recruitment side specifically, AI is being used to match patients to eligibility criteria at a scale and speed that manual review can’t match. Electronic health records, genomic databases, and real-world data are scanned to identify candidates who fit the inclusion criteria but might never have seen a trial recruitment advertisement. For rare disease trials where the eligible population might be a few thousand people globally, this capability isn’t just helpful — it’s the difference between a trial that runs and one that doesn’t.
Our angle here is that AI agents can be built to handle specific steps in the trial workflow autonomously — protocol amendment review, eligibility screening, adverse event flagging — rather than as bolt-on analytics tools that still require manual interpretation. That’s a different kind of engagement than buying a platform licence, and it tends to produce meaningfully different outcomes.
Key figures from current research:
| Metric | Figure |
|---|---|
| AI-powered clinical trials market (2025) | USD 9.17 billion |
| Projected market size by 2030 | USD 21.79 billion (19% CAGR) |
| Reduction in drug discovery costs with AI | Up to 40% |
| Clinical trial enrollment improved by AI recruitment tools | +65% |
| AI predictive models’ accuracy forecasting trial outcomes | 85% |
| AlphaFold public database entries | 200 million+ protein structures |
| Literature systematic review time with AI vs. without | 3–4 weeks vs. 8–12 weeks |
Making sense of massive datasets
Modern biological research generates data at a scale that would have been science fiction twenty years ago. A single genomics study can produce terabytes of sequencing data. A proteomics experiment examining thousands of proteins across hundreds of samples produces datasets that no human team can manually interpret. Multi-omics research — combining genomic, proteomic, metabolomic, and clinical data — creates integration challenges that are essentially impossible without computational tools.
This is where machine learning shows some of its most practical value in research contexts. ML models trained on multi-omics data can identify biomarkers that predict treatment response, find subpopulations within a disease that respond differently to the same drug, and flag patterns in longitudinal data that would take a human analyst months to surface. One concrete example: a deep learning model trained on clinical imaging data achieved 87% sensitivity and 92% specificity in distinguishing COVID-19 from other lung diseases — faster, and at scale, than any radiologist review process.
The challenge for most research organisations isn’t accessing machine learning. It’s integrating it with the specific data formats, storage systems, and analysis pipelines they’re already using. A pharmaceutical company running a clinical programme on Medidata Rave needs AI tools that work with that system, not tools that require a parallel data infrastructure. This is the integration problem that kills most AI pilots — and it’s precisely why custom-built solutions outperform generic ones in this space.
AI agents and the self-driving research loop
The most interesting development in AI for research over the last two years isn’t any single model. It’s the emergence of autonomous AI agents that can execute multi-step research tasks without human intervention at each step. In practical terms: an agent that receives a research question, queries literature databases, extracts relevant studies, synthesises findings, identifies gaps, and outputs a structured report — without a researcher doing each of those steps manually.
Some organisations are taking this further, into what’s being called self-driving laboratories. The loop looks like this: AI proposes an experiment, robotic systems run it, AI analyses the results, and the model updates its hypothesis and proposes the next experiment — all within hours rather than weeks. This isn’t science fiction. It’s operational at a small number of cutting-edge research organisations, and it’s the direction the whole field is heading.
For most organisations, the starting point isn’t a fully autonomous lab. It’s deploying AI assistants that handle specific high-volume, low-judgment tasks: literature screening, data formatting, report generation, regulatory document drafting. These are tasks that currently consume a significant portion of a research team’s time without requiring the kind of expertise that actually advances science. Automating them frees researchers to spend more time on the questions that actually need their expertise.
Our enterprise AI team has worked on exactly this kind of deployment — building agent systems that integrate with existing research infrastructure rather than sitting alongside it. The difference in adoption rates is significant: agents that work within familiar tools get used; standalone platforms often don’t.
The honest part: limitations, reproducibility, and where AI still falls short
Any article on AI in research that doesn’t address the limitations isn’t being straight with you. So here’s the part we think matters most for anyone making decisions about deploying AI in a research context.
Reproducibility is a real problem
AI models are trained on data. If that data has biases — over-representation of certain populations, certain disease types, certain experimental conditions — the model will reproduce those biases in its outputs. In drug discovery, this can mean models that perform brilliantly on well-studied proteins and poorly on rare ones. In clinical trial design, it can mean predictions that are accurate for the patient populations that dominate historical trial data and less accurate for everyone else. Knowing this doesn’t make the problem disappear, but it does change how you validate AI outputs before acting on them.
Hallucination in research contexts is specifically dangerous
Large language models sometimes produce confident-sounding outputs that are factually wrong. In a consumer chatbot, this is annoying. In a research automation context — where an AI assistant is summarising clinical evidence or extracting data from studies — it’s a serious risk. Every production system we build for research applications includes verification steps and human review gates at the points where errors would be most consequential. Any vendor or partner that doesn’t discuss this is either not thinking about it or not being honest with you.
Integration is still where most projects fail
Back to that MIT figure: 95% of enterprise AI pilots failing to deliver measurable impact. The causes, consistently, are disconnection from real workflows, poor data foundations, and unclear ownership of the output. This isn’t a technology problem — it’s a systems and process problem. It’s why the starting point for any engagement our AI consulting team takes on is understanding the existing workflow, not the desired AI capability.
FAQ
Both, depending on which part of research you’re talking about. In drug discovery, it’s genuinely transforming the early stages — protein structure prediction, molecular design, target identification. The 2024 Nobel Prize in Chemistry went to Demis Hassabis and the AlphaFold team for work that solved a fifty-year-old problem in structural biology. That’s not hype.
Pharmaceuticals and biotech are the clear leaders. Drug discovery was the first area where AI moved from helpful tool to structurally important infrastructure, and the gap between organisations using it and those not is becoming measurable in years of competitive advantage.
After that, financial research — particularly quantitative analysis and market intelligence — has seen substantial AI adoption, mostly because the data is structured, plentiful, and the feedback loops are fast. Materials science and energy research are moving quickly too. Academic biomedical research is adopting AI for literature synthesis and data analysis faster than most people expected. The sectors still in the early stages tend to be those where data is fragmented, proprietary, or poorly structured — which is a solvable problem, but it takes real investment.
The honest answer is neither, fully. AI doesn’t replace the scientific judgement that decides which questions are worth asking, which anomalies in data are interesting, or which failure should change the experimental direction. Those remain human calls.
What AI does — when it’s actually working — is remove the parts of research that don’t require those judgements. Reading and synthesising literature. Screening thousands of compounds. Running the same data transformation pipeline for the twentieth time. Pattern-matching across datasets too large for human review. Researchers using AI well aren’t doing less science. They’re spending more of their time on the parts of science that actually require them.
The speed gains are concentrated in the early phases. Traditional drug discovery from target identification to preclinical candidate nomination typically takes three to five years. AI-assisted workflows are compressing that to 12–18 months in well-documented cases. Insilico Medicine’s ISM001-055, a drug with both target and molecule designed by AI, reached Phase IIa from target identification in 18 months and published positive results in Nature Medicine in 2025. That timeline would have been three to four years through traditional methods.
The mechanism isn’t mysterious. AI can screen far more molecular candidates than any human team, predicts how a molecule will interact with a target without running every experiment physically, and learns from each failed candidate to make the next generation of designs better. Novartis estimated AI reduced their drug discovery costs by up to 40%. MIT researchers used generative AI to design novel antibiotics against drug-resistant bacteria in 2025 — a category where traditional methods had run out of ideas.
Three things come up consistently in our experience. The first is data bias. AI models learn from the data they’re trained on. If that data over-represents certain populations, certain disease types, or certain experimental conditions, the model reproduces those biases in its outputs. In drug discovery, this means models that perform brilliantly on well-studied targets and poorly on rare disease proteins. In clinical prediction, it means accuracy figures that don’t hold up across patient populations that weren’t well-represented in historical trials.
The second is the integration problem. Generic AI tools that aren’t connected to a research organisation’s specific data infrastructure, instruments, and workflows tend to sit unused or get used for peripheral tasks. The 95% pilot failure rate comes from this more than from model capability.
The third is hallucination in high-stakes contexts. A general-purpose language model that confidently states an incorrect molecular property or invents a plausible-sounding but fictional citation isn’t just unhelpful — it’s a risk. Any AI system deployed in research needs verification checkpoints at the points where errors would be consequential.
It depends almost entirely on the state of the data and the complexity of the integration. A focused tool — say, an AI-powered literature screening system connected to a specific set of databases and outputting into an existing workflow — typically takes 8–12 weeks from specification to deployment. A broader system with custom model training on proprietary data, integration with multiple internal platforms, and an ongoing monitoring pipeline is a longer engagement.
The first conversation is always a scoping session. We don’t give timeline estimates before we understand the data situation, because the data situation is what determines the timeline. If that’s where you are, the AI consulting conversation is the right starting point.
Research moves at the speed of its tools
The competitive advantage in research — whether you’re a pharmaceutical company, an academic institution, or an enterprise R&D function — increasingly comes down to how quickly you can move through the discovery cycle. That means reading faster, screening faster, designing better experiments, and interpreting results with fewer blind spots.
AI won’t replace researchers. But researchers using AI will, over time, substantially outperform researchers who aren’t. The question isn’t really whether to adopt AI in research. It’s whether to build the capability properly — integrated with your data, your tools, and your workflows — or to patch together generic tools and wonder why the results don’t match the case studies.We build custom AI systems for research-intensive organisations: pharma, biotech, financial research, and enterprise R&D. Every project starts with the same question: where is your team losing the most time to work that doesn’t require their expertise? The answer to that question is usually where the best AI investment begins.